Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
Status:
Completed
Trial end date:
2016-08-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see how much of the drug Yervoy can be safely tolerated when
it is given to people who are also receiving a drug called Sylatron. Investigators also wish
to find out whether the addition of Yervoy increases the chance that Sylatron will cause a
rise in the level of antibodies in the patient's blood that recognize their own tissues,
known as "autoimmune" antibodies. Investigators also want to find out how likely it is that
their tumor will shrink.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute